David Bruce Hedden

20220370367, Nov 24, 2022

Aug 5, 2022

17/881714

- Boston MA, US
David Bruce HEDDEN - Bristol TN, US
Kristen Marie LESKOW - Watertown MA, US

A61K 9/20
A61K 45/06
A61K 38/10
A61K 31/197
A61K 31/4439
A61K 31/506
A61K 9/00
A61K 31/785

Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bile acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H-receptor antagonists, y-aminobutyric acid-I3 (GABA-B) agonists, prodrugs of GABA-B agonists, acid pump antagonists, protease inhibitors and GC-C agonists.

20210267903, Sep 2, 2021

May 7, 2021

17/314213

- Boston MA, US
David Bruce HEDDEN - Bristol TN, US
Kristen Marie LESKOW - Watertown MA, US

A61K 9/20
A61K 45/06
A61K 38/10
A61K 31/197
A61K 31/4439
A61K 31/506
A61K 9/00
A61K 31/785

Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bile acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H-receptor antagonists, y-aminobutyric acid-I3 (GABA-B) agonists, prodrugs of GABA-B agonists, acid pump antagonists, protease inhibitors and GC-C agonists.

20210015754, Jan 21, 2021

Sep 30, 2020

17/039662

- Boston MA, US
David Bruce HEDDEN - Bristol TN, US
Kristen Marie LESKOW - Watertown MA, US

A61K 9/20
A61K 45/06
A61K 38/10
A61K 31/197
A61K 31/4439
A61K 31/506
A61K 9/00
A61K 31/785

Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bile acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H-receptor antagonists, y-aminobutyric acid-I3 (GABA-B) agonists, prodrugs of GABA-B agonists, acid pump antagonists, protease inhibitors and GC-C agonists.

20170266116, Sep 21, 2017

Feb 27, 2017

15/443747

- Cambridge MA, US
David Bruce HEDDEN - Bristol TN, US
Kristen Marie Leskow - Watertown MA, US

Ironwood Pharmaceuticals, Inc. - Cambridge MA

A61K 9/20
A61K 31/197
A61K 31/4439
A61K 31/506
A61K 31/785
A61K 38/10
A61K 45/06
A61K 9/00
A61K 9/28

Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bile acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H-receptor antagonists, γ-aminobutyric acid-β (GABA-B) agonists, prodrugs of GABA-B agonists, acid pump antagonists, protease inhibitors and GC-C agonists.

20160015644, Jan 21, 2016

Jan 14, 2014

14/760883

- Cambridge MA, US
David Bruce HEDDEN - Baltimore MD, US
Kristen Marie LESKOW - Boston MA, US

IRONWOOD PHARMACEUTICALS, INC. - Cambridge MA

A61K 9/20
A61K 31/785

Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bite acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H-receptor antagonists, γ-aminobutyric acid-β (GABA-B) agonists, prodrugs of GABA-B agonists, acid pump antagonists, protease inhibitors and GC-C agonists.